ArticlePoultry science2026
Reducing eukaryotic viruses while preserving the phageome to achieve a safer virome for fecal virome transplantation.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The virome plays a significant role in maintaining the gut health of the host. Fecal virome transplantation (FVT), a burgeoning therapeutic strategy, holds promise in regulating intestinal microecology and treating associated diseases. However, the presence of eukaryotic viruses in FVT poses potential risks, which may compromise its safety and efficacy. This study leverages the key distinction between bacteriophages and eukaryotic viruses-namely, the presence or absence of an envelope-to reduce the burden of eukaryotic viruses in samples via solvent/detergent (S/D) treatment, while preserving the biologically active phageome. To this end, fecal samples were collected from healthy AA broilers, and the virome was isolated and subjected to S/D treatment. Subsequent DNA virome sequencing analysis was conducted to evaluate the impact of this treatment. The results indicated that S/D treatment tended to decrease the relative abundance of eukaryotic viral families (e.g., Adenoviridae, Parvoviridae), while bacteriophages remained the dominant viral component. α-diversity analysis revealed no significant differences in overall viral diversity post-treatment. However, β-diversity analysis indicated shifts in viral community composition. Further differential virus analysis revealed a significant increase in the relative abundance of specific bacteriophages following treatment. Finally, functional analysis of the virome revealed a diverse array of genes involved in DNA metabolism and host cell wall remodeling. Notably, the primary functional distinction between FVT0 and FVT1 was the attenuated response to eukaryotic viruses in FVT1. Collectively, this study suggests that S/D treatment may reduce the abundance of eukaryotic viruses in FVT, thereby enhancing clinical safety. These findings provide a theoretical basis and methodological support for the safe application of FVT in the treatment of animal diseases, paving the way for more secure and effective viral therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.